Gyala Therapeutics initiates Phase I/IIa clinical trial of a CAR-T cell therapy in acute leukemias with limited treatment options
BARCELONA, Spain, Feb. 10, 2026 /PRNewswire/ — Gyala Therapeutics, a clinical-stage biotechnology company developing innovative cell therapies for hematologic malignancies, today announced the initiation of a Phase I/IIa clinical trial of GYA01
